This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEIA90DU_L.jpg
LONDON (Reuters) – AstraZeneca (NASDAQ:AZN) is no longer pursuing U.S. approval of its COVID-19 vaccine, Chief Executive Pascal Soriot said in a media call on Thursday.
Demand for vaccines in the country is declining and the market is well served by the mRNA shots, he said.
